NasdaqGM - Delayed Quote USD

908 Devices Inc. (MASS)

5.58 -0.02 (-0.36%)
At close: April 19 at 4:00 PM EDT
5.79 +0.21 (+3.76%)
After hours: April 19 at 4:28 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Kevin J. Knopp Ph.D. Co-Founder, CEO, President & Director 788.88k -- 1973
Dr. Christopher David Brown Ph.D. Co-Founder, Chief Product Officer & Co-Chair of Scientific Advisory Board 459.7k -- 1975
Mr. Joseph H. Griffith IV CFO & Treasurer 468.98k -- 1975
Mr. Steve Araiza Co-Founder -- -- --
Mr. Andrew Bartfay Co-Founder & Director of Hardware Development -- -- --
Mr. Michael Jobin Co-Founder & Director of Product Development -- -- --
Dr. Scott Miller Ph.D. Co-founder & Director of MS Engineering -- -- --
Mr. Michael S. Turner Esq., J.D. Chief Legal & Administrative Officer and Secretary 97.84k -- 1967
Mr. Don Osmer Vice President of Human Resources -- -- 1966

908 Devices Inc.

645 Summer Street
Boston, MA 02210
United States
857 254 1500 https://908devices.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
230

Description

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Corporate Governance

908 Devices Inc.’s ISS Governance QualityScore as of April 1, 2024 is 10. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 8; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 07, 2024 - May 13, 2024
908 Devices Inc. Earnings Call

Related Tickers

QTRX Quanterix Corporation
15.83
+0.25%
 
NPCE NeuroPace, Inc.
13.98
-0.14%
 
CNMD CONMED Corporation
72.64
+2.19%
 
CERS Cerus Corporation
1.6800
+2.44%
 
NVRO Nevro Corp.
12.07
-2.03%
 
RPID Rapid Micro Biosystems, Inc.
0.8900
+3.49%
 
KIDS OrthoPediatrics Corp.
30.31
+2.89%
 
IRMD IRADIMED CORPORATION
41.00
+1.59%
 
INGN Inogen, Inc.
6.75
-4.80%
 
NSYS Nortech Systems Incorporated
16.44
+1.99%